Educational theme | Treating systemic mastocytosis

Within this Educational Theme, our second article focuses on the treatment of systemic mastocytosis (SM), a rare hematologic malignancy where...

ASH2021: What are the key highlights in MPN?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis,...

Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques...

Risk factors for thrombotic events in patients with PV and ET

Polycythemia vera (PV) and essential thrombocytopenia (ET) present increased risk of thrombosis, which is associated with poor survival.

Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques...

Risk factors for thrombotic events in patients with PV and ET

Polycythemia vera (PV) and essential thrombocytopenia (ET) present increased risk of thrombosis, which is associated with poor survival.

Diagnostic performance of EPO and JAK2 mutation

A diagnosis of polycythemia vera (PV) is made following various assessments including hemoglobin (Hb) and hematocrit (HCT) levels, red cell mass (RCM)...

Direct oral anticoagulant use in patients with myeloproliferative neoplasms

Myeloproliferative neoplasms (MPN), which include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis...

Responses to mRNA SARS-CoV-2 vaccines in patients with MPN: Findings from two studies

Vaccination against SARS-CoV-2, particularly with spike protein messenger ribonucleic acid (mRNA) vaccines, has...

The influence of MPN on SARS-COV-2 infection, mortality, and thrombotic events

Hematologic malignancies are an underlying risk factor for SARS-COV-2 infection and mortality. More specifically,...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...